June 2016June 2016
New Product - Palexia IR
Palexia IR (tapentadol (as hydrochloride)) is a centrally acting synthetic analgesic combining opioid and non-opioid activity in a single molecule. It has 18 times less binding affinity than morphine to the human mu opioid receptor but was only 2-3 times less potent in producing analgesia in animal models (on a dose per body weight basis). Tapentadol has been shown to inhibit noradrenaline reuptake in the brains of rats resulting in increased noradrenaline concentrations. Palexia IR is indicated for the relief of moderate to severe pain. Palexia IR is contraindicated in situations where drugs with mu-opioid receptor agonist activity are contraindicated, i.e. patients with significant respiratory depression (in unmonitored settings or the absence of resuscitative equipment), and patients with acute or severe bronchial asthma or hypercapnia; in any patient who has or is suspected of having paralytic ileus; in patients with acute intoxication with alcohol, hypnotics, centrally acting analgesics, or psychotropic drugs and in patients who are receiving MAO inhibitors or who have taken them within the last 14 days. Palexia IR is available as 50 mg immediate release tablets in blister packs of 20’s.
Copyright © MIMS Australia Pty Ltd. All rights reserved.
MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au